Literature DB >> 8794511

Depression in schizophrenia: a comparison of three measures.

A A Collins1, G Remington, K Coulter, K Birkett.   

Abstract

Depression, as a feature of schizophrenia, is well established. However, clarifying the exact nature of this relationship has been problematic. The clinical measures routinely utilized to evaluate depression have not been specifically designed for use in schizophrenia, and it is well recognized that a variety of depressive symptoms overlap with other features common to this illness, e.g. negative symptoms, neuroleptic induced side effects. The present study compared three commonly used measures of depression (Hamilton Depression Rating Scale (Ham-D), Calgary Depression Scale (CDS) and the depression subscale of the Positive and Negative Syndrome scale (PANSS-D) in a group of outpatients with schizophrenia, evaluating the degree of association between the scales. Additionally, the relationship between each of the depression measures, negative symptoms and extrapyramidal symptoms (EPS) was calculated. Results revealed that all three measures of depression were significantly correlated, although the CDS was unique in its ability to distinguish between depression, negative symptoms and EPS. It is concluded that the CDS, when compared with the HAM-D and the PANSS-D, is the most suitable measure of depression in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794511     DOI: 10.1016/0920-9964(95)00107-7

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  17 in total

Review 1.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

2.  Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia.

Authors:  Wolfram An der Heiden; Anne Leber; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-23       Impact factor: 5.270

3.  Depression in the long-term course of schizophrenia.

Authors:  Wolfram an der Heiden; Regina Könnecke; Kurt Maurer; Daniel Ropeter; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

4.  Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

Authors:  Donald E Addington; Somaia Mohamed; Robert A Rosenheck; Sonia M Davis; Thomas Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2010-09-21       Impact factor: 4.384

5.  Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Gagan Fervaha; Eric Plitman; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Yukiko Mihashi; Philip Gerretsen; Gary Remington; Benoit Mulsant; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2014-12-30       Impact factor: 4.939

6.  The relationships between depression and remission in first-episode psychosis.

Authors:  Piet Oosthuizen; Robin Emsley; Dana Niehaus; Liezl Koen; Bonga Chiliza
Journal:  World Psychiatry       Date:  2006-10       Impact factor: 49.548

7.  Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis.

Authors:  Jean Addington; Hely Shah; Lu Liu; Donald Addington
Journal:  Schizophr Res       Date:  2014-01-16       Impact factor: 4.939

8.  The Motivation and Pleasure Scale-Self-Report (MAP-SR): reliability and validity of a self-report measure of negative symptoms.

Authors:  Katiah Llerena; Stephanie G Park; Julie M McCarthy; Shannon M Couture; Melanie E Bennett; Jack J Blanchard
Journal:  Compr Psychiatry       Date:  2013-01-22       Impact factor: 3.735

9.  Neurocognitive impairment in the deficit subtype of schizophrenia.

Authors:  Gagan Fervaha; Ofer Agid; George Foussias; Ishraq Siddiqui; Hiroyoshi Takeuchi; Gary Remington
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-11       Impact factor: 5.270

10.  Assessing depression in youth at clinical high risk for psychosis: a comparison of three measures.

Authors:  Jordan E DeVylder; Lawrence H Yang; Jill M Harkavy-Friedman; Neyra Azimov; Deborah J Walder; Cheryl M Corcoran
Journal:  Psychiatry Res       Date:  2013-12-10       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.